Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells

International Journal of Cancer

Volumn 101, Issue 4, 2002, Pages 353-359

  Mangino, Giorgio ^a,c   Grazia Capri, Maria ^a   Barnaba, Vincenzo ^b   Alberti, Saverio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c INSTITUT PASTEUR   (France)

Author keywords

Adoptive immunotherapy; Antigen presenting cell; Cancer; Cytotoxic T lymphocytes; Major histocompatibility complex

Indexed keywords

HLA ANTIGEN CLASS 1; INTERCELLULAR ADHESION MOLECULE 1; TROP 2 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVITY; CELL GROWTH; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FIBROBLAST; GENETIC CODE; GENETIC TRANSFECTION; GERM LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR CELL;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD80; ANTIGENS, NEOPLASM; BETA 2-MICROGLOBULIN; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; FIBROBLASTS; GENETIC ENGINEERING; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A2 ANTIGEN; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE ACTIVATION; MICE; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036780780     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10616     Document Type: Article

References (66)

1. Interferon-γ induces different subunit organizations and functional diversity of proteasomes
2. Immunofluorescence analysis in flow cytometry: Better selection of antibody-labeled cells after fluorescence overcompensation in the red channel
3. DNA methylation prevents transfection of genes for specific surface antigens
4. Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: Formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2
5. A single laser method for subtraction of cell autofluorescence in flow cytometry
6. T-cell-receptor engagement and tumor ICAM-1 up-regulation are required to by-pass low susceptibility of melanoma cells to autologous CTL-mediated lysis
7. Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions
8. Professional presentation of antigen by activated human T cells
9. The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303
10. Proteasome and Class I antigen processing and presentation
11. Differential presentation of the same MHC Class I epitopes by fibroblasts and dendritic cells
12. Large and diverse numbers of human diseases with HIKE mutations
13. The dendritic cell and human cancer vaccines
14. High-efficiency expression gene cloning by flow cytometry
15. A comprehensive set of sequence analysis programs for the VAX
16. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes
17. Cloning of the gene encoding TROP-2, a cell-surface glycoprotein expressed by human carcinomas
18. Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules
19. + T lymphocytes in the P815 tumor system in vitro
20. + T cell adoptive immunotherapy
21. + cytotoxic T lymphocytes in the absence of exogenous help
22. Purification and coupling of fluorescent proteins for use in flow cytometry
23. Initial clinical evaluation of two murine IgG2a monoclonal antibodies for immunotherapy of gastrointestinal carcinoma
24. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules
25. A triad of costimulatory molecules synergize to amplify T-cell activation
26. In vivo activation of antigen-specific Cd4 T cells
27. HLA Class 1 genes: From structure to expression, serology and function
28. Vaccine T-cell epitope selection by a peptide competition assay
29. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells
30. Expression of human Class I histocompatibility antigens at the surface of DNA-transformed mouse L cells
31. Expression of T-cell-antigen-receptor heterodimers in a lipid-linked form
32. Retroposition in a family of carcinoma-associated antigen genes
33. Telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation
34. Optimizing dendritic cell function by genetic modification
35. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors
36. Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocytecolony stimulating factor (GM-CSF)
37. Peripheral T cell tolerance
38. Immunological adjuvants promote activated T cell survival via induction of Bcl-3
39. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
40. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells
41. Natural T-cell response against MHC Class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer
42. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A, B, C, antigens
43. 2-microglobulin specifically enhances cell-surface expression of HLA Class I molecules in transfected murine cells
44. Characterizing T-cell epitopes in vaccine candidates
45. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinomalong-lasting, complete remissions can be induced
46. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
47. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma
48. The human Trop-2 is a tumor-associated calcium signal transducer
49. Immunotherapy and gene therapy of cancer
50. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1
51. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells
52. + lymphocytes as compared with nonprofessional APC
53. Biochemical and immunological characterization of the human carcinoma-associated antigen MH 99/KS 1/4
54. Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A)
55. ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM
56. Antigen-presenting cells. Professionals and amateurs
57. Characterization of cluster 13: The epithelial/carcinoma antigen recognized by MAb RS7
58. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA Class II matrices
59. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products
60. + T cells by B7-transfected melanoma cells
61. Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule
62. Differential processing of Class-I-restricted epitopes by the standard proteasome and the immunoproteasome
63. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine
64. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
65. Combinatorial peptide libraries and biometric score matrices permit the quantitative analysis of specific and degenerate interactions between clonotypic TCR and MHC peptide ligands